Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Company Drug

Ascentage Pharma’s Olverembatinib Showcases Promising Results at ASH Annual Meeting

Fineline Cube Nov 3, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has presented the latest results of multiple studies regarding its...

Company Medical Device

Sino Medical Sciences Technology Secures TFDA Approval for HT Supreme Drug-Eluting Stent System

Fineline Cube Nov 3, 2023

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical technology company, has announced that...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for Phase I Clinical Study of B019 CAR-T Cell Injection

Fineline Cube Nov 3, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA

Fineline Cube Nov 3, 2023

China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...

Company

Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances

Fineline Cube Nov 3, 2023

Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...

Company

Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales

Fineline Cube Nov 3, 2023

US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...

Company Drug

Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program

Fineline Cube Nov 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...

Company Deals

AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies

Fineline Cube Nov 2, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...

Company

Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023

Fineline Cube Nov 2, 2023

Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...

Company Drug

EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting

Fineline Cube Nov 2, 2023

Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...

Company

GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%

Fineline Cube Nov 2, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development

Fineline Cube Nov 2, 2023

Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...

Company Drug

Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...

Company

Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials

Fineline Cube Nov 2, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...

Company Drug

Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China

Fineline Cube Nov 2, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...

Company Drug

Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial

Fineline Cube Nov 2, 2023

China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...

Company Drug

Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial

Fineline Cube Nov 2, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...

Company Drug

Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study

Fineline Cube Nov 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...

Company Deals

3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab

Fineline Cube Nov 2, 2023

China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...

Company Deals

Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma

Fineline Cube Nov 2, 2023

US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...

Posts pagination

1 … 480 481 482 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.